NKTR

Nektar Therapeutics

September 22, 2026 · intraday

Rarity

1.97

Peak move

−10.24%

Float cap

$1.3B

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company focused on immunotherapy. It discovers and develops immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses. Its pipeline targets autoimmune diseases, including atopic dermatitis and alopecia areata, and cancer, advancing drug candidates through preclinical and clinical development.

• index_rebalanceSep 11

  Nektar Therapeutics was added to the S&P Biotechnology Select Industry Index and removed from the S&P Pharmaceuticals Select Industry Index on 11 September 2026, changing its grouping within sector benchmarks.

  Websimplywall.st
• litigation_outcomeSep 10

  Nektar Therapeutics' damages expert testified to a California federal jury that Eli Lilly could owe the company nearly $1 billion if the jury finds Lilly breached a license agreement to co-develop Nektar's autoimmune-disease drug Rezpeg.

  Weblaw360.com
• litigation_outcomeSep 8

  Opening statements began in Nektar Therapeutics' $1 billion breach-of-contract suit against Eli Lilly in California federal court, where Nektar alleges Lilly sabotaged development of the autoimmune drug Rezpeg, and a Lilly executive testified his note calling Nektar 'desperate' referred to the company's need for Rezpeg to succeed.

  Weblaw360-687022171.us-east-1.elb.amazonaws.comWeblaw360.co.uk
• reg_fd_disclosureSep 8

  Nektar Therapeutics disclosed in an 8-K (Item 7.01) that it entered a quiet period effective September 8, 2026, lasting until public announcement of 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata.

  Webir.nektar.com